Has Jiwoon Chang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $43,852 in general payments to Jiwoon Chang, MD across 48 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jiwoon Chang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jiwoon Chang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jiwoon Chang, MD

Pulmonary Disease · Stanford, CANPI 1952780694

Payments from drug & device makers

$43,852in general payments, 2019–2025

Across 48 payments — averaging $913.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pulmonx Corporation$27K
Johnson & Johnson$12K
Intuitive Surgical$3K
Ambu Inc.$1K
Steris Corporation$180
ERBE USA Inc$29

What the payments were for

Consulting fees$39,54590%
Speaking & faculty fees$5001%
Travel & lodging$210%
Food & beverage$1,2863%
Education$2,5006%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pulmonx Corporation	36	$27,072
Johnson & Johnson	5	$12,422
Intuitive Surgical	4	$3,023
Ambu Inc.	1	$1,125
Steris Corporation	1	$180
ERBE USA Inc	1	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,852 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California →

Medicare billing

Part B allowed, 2024

$117,427

Medicare patients

334

Services billed

1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Albuterol Sulfate HfaAlbuterol Sulfate	18	$425

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Stanford

Roham ZamanianStanford$1.7M
Revati ShreeniwasStanford$726K
Joe HsuStanford$478K
Toby MaherLos Angeles$27.6M
David PhamWestminster$5.9M
Andrew WachtelLos Angeles$5.9M
Aaron WeinbergIrvine$5.1M
Michael RothLos Angeles$4.5M
Namita SoodSacramento$3.7M
Edward FedermanSan Diego$3.6M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →